Ascendis Pharma A/S (Ascendis Pharma A/S) Research & Development

: $445.4 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Research & Development is the aggregate amount of research and development expenses during the year. Ascendis Pharma A/S's Research & Development for the three months ended in Dec. 2023 was $99.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $445.4 Mil.

Ascendis Pharma A/S Research & Development Historical Data

The historical data trend for Ascendis Pharma A/S's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

212.91

317.40

334.31

402.14

450.88

Ascendis Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development																115.06	113.61	113.78	118.93	99.11

Ascendis Pharma A/S Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $445.4 Mil.

Ascendis Pharma A/S (NAS:ASND) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ascendis Pharma A/S Research & Development Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.